18 June 2020 in Artificial Organs
13 November 2024 in US Cardiology Review
Learn more about the management of atrial myxoma with severe pulmonary hypertension in this free article from USC Journal. Left Atrial Myxoma.
1 May 2024 in Circulation: Arrhythmia and Electrophysiology
26 June 2026 in Reviews in Cardiovascular Medicine
Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide and is associated with substantial morbidity, increased stroke risk, and a significant healthcare burden. While antiarrhythmic medications and catheter ablation remain central to rhythm control strategies, the efficacy of these therapies declines in persistent and long-standing persistent AF. Surgical ablation has consistently demonstrated superior long-term rhythm control, but this approach remains underutilized due to the associated perceived invasiveness and procedural complexity. Meanwhile, advances in energy sources have transformed the field, with bipolar radiofrequency (RF) and cryoablation established as the gold standard for lesion creation, supported by decades of durable outcomes. Nonetheless, both modalities possess limitations related to thermal injury and technical demands. Pulsed-field ablation (PFA), a non-thermal modality that induces irreversible electroporation (IRE), represents a promising new direction. Indeed, PFA preferentially ablates cardiomyocytes while sparing adjacent structures, enabling rapid, reproducible lesion formation with an improved safety profile. Preclinical studies have demonstrated the ability of this technology to create transmural lesions. Meanwhile, catheter-based studies have shown the associated efficacy and safety with this technology, and early feasibility trials suggest that surgical PFA clamps can replicate most of the Cox-Maze lesion set. Current surgical ablation lesion sets rely primarily on RF or cryoablation. However, emerging modalities such as PFA are poised to enable effective epicardial ablation on the beating heart, a challenge for thermal-based ablation technologies. With the advent of hybrid strategies that combine epicardial surgical ablation with catheter-based endocardial ablation, PFA may broaden the role of surgical ablation in advanced AF.
12 February 2026 in Journal of Electrocardiology
Noninvasive Electrocardiographic Imaging (ECGI) was used to define the mechanisms of atrial fibrillation (AF) in mitral regurgitation (MR), which remain poorly understood. Seventeen patients with degenerative MR and AF undergoing were studied. Thirteen age-matched patients with lone AF provided a control group. Epicardial electrograms were constructed noninvasively with ECGI using 256 body surface electrocardiograms and patient-specific heart-torso geometry from delayed-enhancement magnetic resonance imaging (DE-MRI) or computed tomography (CT) scans. Bi-atrial epicardial activation time maps and phase maps were generated. AF drivers were classified as focal (radial activation) or rotors (high curvature wavefront rotating about a center). Left atrial (LA) fibrosis was quantified from the DE-MRI scans in 5 MR patients. The LA and right atrium (RA) harbored 61% and 36% of drivers, respectively and the anterior inter-atrial groove had 3% of the sources. 51% of the drivers were mapped in the posterior LA. One third of drivers occurred repeatedly. The left PV and LA appendage regions had the most repetitive drivers. Activation patterns varied from single macro-reentry to simultaneous wavelets resulting in wave breaks and collisions. Driver distribution and activation patterns remained similar between MR and lone AF groups, except stable rotors were not observed in MR. DE-MRI maps showed bi-atrial fibrosis. Drivers and discontinuous wavefront propagation were often localized in fibrotic regions. AF activation patterns in MR were complex and exhibited spatio-temporal variability. Bi-atrial drivers were present. The posterior LA harbored the highest percentage of drivers. This region also exhibited fibrosis in a subset of patients, suggesting that it may play a role in creating the AF substrate.
19 September 2026 in The Journal of Thoracic and Cardiovascular Surgery